No science talk... just free market capitalism here. I hear buyout, buyout, buyout when it comes time for big pharma (Roche, Pfizer, Celgene, whoever) to play Let's Make a Deal. With a significant pipeline for a small cap biotech, wouldn't licensing each product individually produce a better return? I don't believe fellow shareholders Leo or Dr Menon would hand over the keys to a company looking for a quantity discount.
Market Data 
Markets 
AI
